DealShare Acquisition Talks with Truemeds for $90M

In a significant development within India's e-commerce and healthcare sectors, social commerce platform DealShare is reportedly in discussions for an acquisition by online pharmacy Truemeds. The proposed transaction values DealShare at approximately $90 million, a stark contrast to its peak valuation of $1.68 billion achieved in early 2022. This valuation is notably close to the company's current cash reserves, signaling a dramatic shift in its market standing.

The potential deal structure, an all-stock transaction, means Truemeds would issue its own shares to DealShare's investors rather than disbursing cash. This approach implies a valuation for Truemeds nearing $600 million, a substantial increase from its last reported funding round in October 2024, which valued the company at $330 million. This strategic move allows Truemeds to absorb DealShare's cash without impacting its own treasury, while potentially leveraging its own equity for the acquisition.

DealShare's journey from a celebrated unicorn to a company seeking an exit at a fraction of its former worth reflects the intense market pressures and strategic pivots experienced by many startups. The company, founded in 2018, saw its valuation soar with backing from prominent investors including Tiger Global, Alpha Wave, and WestBridge Capital. However, recent years have been marked by significant challenges. In 2023, DealShare ceased its B2B operations and underwent substantial layoffs, while its closest competitor, Meesho, achieved profitability. Financial performance further deteriorated, with revenue plummeting by 74% in FY24 and continuing to decline in FY25, albeit with narrowed losses.

The departure of all four co-founders—Vineet Rao, Sankar Bora, Sourjyendu Medda, and Rajat Shikhar—over the past few years underscores the internal shifts preceding this potential acquisition. The current discussions with Truemeds, which has demonstrated robust growth with 66% revenue expansion and a customer base of 500,000 monthly users, highlight a consolidation trend in the Indian startup ecosystem. This trend is further evidenced by recent M&A activities, such as Groww's acquisition of Fisdom and InCred Money's purchase of Stocko, many of which involved companies exiting at valuations below their previous investor expectations.

A notable aspect of this potential deal is the involvement of WestBridge Capital, an investor holding stakes in both DealShare and Truemeds. While not inherently problematic, this dual interest adds a layer of complexity to the valuation discussions. The investor's position could influence the perceived value of Truemeds' shares used in the stock swap, particularly as they absorb a company whose valuation has been significantly marked down. This situation raises questions about the true recovery for DealShare's earlier investors, who backed the company at earlier, lower valuations.

The proposed acquisition, if finalized, would represent a significant discount of approximately 95% from DealShare's 2022 peak. The success of this transaction hinges not only on the final terms but also on Truemeds' ability to justify its elevated valuation in future independent funding rounds. For investors, the key metric to watch will be whether the $600 million valuation for Truemeds reflects sustainable growth or is primarily a construct to facilitate this specific stock-swap acquisition, determining whether this marks a genuine recovery or a carefully managed exit.